Peptide Insider

Adamax Side Effects: What the Evidence Actually Shows

Adamax side effects — what the evidence actually shows

Written by Marcus Reinhardt · Lead Analyst, Peptide Insider · LinkedIn

Evidence-first peptide coverage — every claim on this page is linked to its primary source and reviewed against our editorial policy

Citations verified against PubMed · Published: 2026-09-04 · Last updated: 2026-09-07

Adamax side effects have never been measured — not in a human trial, not in an animal, not in a cell culture. PubMed has no study of Adamax at all. What exists is a Wikipedia entry, a June 2025 New Zealand regulatory submission naming it among border-seizure products, and Russian clinical research on Semax, the heptapeptide it was designed from. Most “Adamax side effects” articles quietly relabel Semax research as Adamax research. We won’t.

Quick Answer: What the Adamax Side-Effect Data Actually Shows

There is no published safety data for Adamax — human, animal, or in vitro. Every safety claim attached to it traces to Semax, a different molecule; the caps and residues Adamax adds can change pharmacology in either direction. The Semax record is thin: one Semax tolerability study reported a “minor percent of side-effects” without stating the percent (PMID 15792140), and a 73-patient Semax study recorded EEG paroxysmal activity after injection in some brain-injured patients (PMID 10199046). Self-reported experiences from Reddit are summarized further down; they are anecdotes, not data.

★The Documented Experience: Zero Monitored Humans

For our cagrilintide and eloralintide pages, this box summarizes what monitored trial participants went through. For Adamax: no human being has ever taken it under study conditions where side effects were recorded — not even tissue in a dish. The nearest documented experience belongs to Semax patients in Russian stroke wards, on a different molecule.

Plenty of people use Adamax. Their experiences have never been collected, controlled, or published. That’s the entire safety picture.

When we publish an individual account here, it will be a real person, named with permission — like the reader experience on our hair-growth guide. We don’t write fiction into this slot.

Research peptide vial

Looking for Lab-Tested Peptides?

Our top-rated vendor publishes batch COAs and third-party testing on every compound — get up to 30% off your first order.

Shop Amino Club →

Affiliate link — it doesn’t change what we report. All compounds sold strictly for non-human research use. Read our full Amino Club review.

In This Guide

What Is Adamax?

Adamax is a designer analogue of Semax. Wikipedia gives its sequence as Ac-MEHFPGPAG-NH2, formula C50H69N11O11S, molar mass 1032.23 g/mol — Semax’s Met-Glu-His-Phe-Pro-Gly-Pro core (PMID 24661604) with an acetyl cap in front, two extra residues behind, and an amide cap at the end, modifications borrowed, per the entry, from Peptide 021. It has no developer, no clinical program, and no published study. Our Adamax research guide covers structure and stability; our Semax spray page covers the parent. This page covers the safety question — which for Adamax means covering an absence honestly.

How It’s Thought to Work

Every mechanistic claim about Adamax is a claim about Semax. Semax is an ACTH(4-10) analogue “completely devoid of any hormonal activity” that stimulates memory and attention in rodents and humans after intranasal application and, in animal studies, stimulates central BDNF synthesis (PMID 16996699). In rats after cerebral artery occlusion, Semax activated Bdnf, TrkC, and TrkA transcription at 3 h (PMID 19633950), and its most marked effect was immunological: immune-response genes made up over 50% of all genes Semax altered (PMID 24661604). All Semax. Whether Adamax’s caps and extra residues preserve, amplify, or alter any of this has never been tested; Medsafe’s verdict on the class: “Their mechanism of action is often unknown” (Medsafe, June 2025). See our peptides for brain health guide for the wider category.

KEY TAKEAWAY

Adamax borrows Semax’s mechanism the way a cover band borrows a setlist — same songs on paper, no guarantee about the performance. Every “how it works” claim on an Adamax listing is a Semax finding plus an untested assumption.

The Evidence Base: Zero Adamax Studies

Search PubMed for Adamax or Ac-MEHFPGPAG-NH2 and nothing comes back — no cell, animal, or human study, no case report; even AHK-Cu has one laboratory paper. A side-effect profile requires humans receiving the compound, a control group, systematic recording, and publication; Adamax has none of the four. “No data” cuts both ways: nothing proves harm, nothing demonstrates safety. What exists is bridge literature about a different molecule — Russian Semax studies in stroke and brain injury, one placebo-controlled Semax fMRI study, and rat transcriptome work. Medsafe said the same of the class: “little is known about their side effects or long-term effects” (Medsafe, June 2025).

PERSONAL OBSERVATION — PI EDITORIAL

We read the listings and articles ranking for “Adamax side effects.” The pattern: a short list of mild, uncited effects and, in the more careful pieces, Semax papers cited as though they were Adamax papers. A compound with no literature had acquired a side-effect profile by inheritance. The list describes the parent — not what is in the vial.

The Semax Clinical Record

The Semax literature is the only human data available. The 1997 Semax study: 30 acute hemispheric stroke patients versus 80 controls on conventional therapy, “some influence” on recovery, no adverse-event data in the abstract (PMID 11517472). The 2005 Semax study of one hundred and eighty-seven patients with cerebrovascular insufficiency was designed to evaluate tolerability and concluded the drug “is featured by minor percent of side-effects and is well tolerated by patients, including those of older age groups” — the percent is not stated, no effect named (PMID 15792140). The 2018 Semax study followed 110 post-stroke patients through early or late rehabilitation, reporting higher plasma BDNF and better Barthel recovery with Semax; its abstract reports no adverse events at all — not “none occurred,” simply none reported (PMID 29798983). The shape — efficacy-focused, in stroke patients, largely without placebo, as with Pinealon — gives no rate and says nothing about Adamax.

The One Recorded Semax Safety Signal

One Semax paper contains a safety observation. A 1999 Semax study followed 73 patients with posthypoxic encephalopathy and reported: “In some cases EEG showed episodes of paroxysmal activity after semax injection, and therefore, the first injection should be carried out with monitoring bioelectric activity of the brain” (PMID 10199046). Read it for what it is: a Semax finding, in brain-injured patients, by injection, unquantified, silent about healthy nasal-spray users. The one time a Semax paper flagged a safety concern, the answer was EEG monitoring during the first dose — a safeguard no research-market buyer has. Whether Adamax carries the same signal is unexamined.

Intranasal and Injectable Use

Most Adamax is used as a nasal spray, copying Semax’s best-known route. The Semax intranasal record in our file is the fMRI study — 1% Semax in 14 subjects versus placebo in 10, measuring network topography, not tolerability (PMID 30225715) — and the hypothesis paper noting intranasal Semax stimulates memory and attention (PMID 16996699). Neither reports nasal irritation rates; neither is about Adamax. Injection is emptier still: studies of injected Adamax number zero, and the parent’s one route-specific safety signal came from injected Semax. What’s assumed, without evidence, is that Adamax behaves like Semax by whichever route.

PRACTICAL NOTES — STANDARD INTRANASAL-PRODUCT HANDLING

  • A nasal spray is a formulated product — vehicle, preservative, and pH affect nasal tolerability; whatever turns a lyophilized vial into a spray is the buyer’s own chemistry, not the defined 1% solution the Semax fMRI study used
  • Reconstituted solutions are temperature- and time-sensitive — our peptide nasal spray guide covers handling

Why the Terminal Modifications Matter

The Adamax pitch assumes capping both ends of Semax and adding two residues is a neutral edit. Semax’s own literature shows how sequence-sensitive this class is: Semax is an ACTH(4-7) fragment plus the tripeptide Pro-Gly-Pro, and tested alone in ischemic rats, PGP diverged from full Semax — Semax selectively altered neurotrophin transcription while PGP’s influence “was mainly unspecific” (PMID 19633950), and PGP attenuated immune activity while Semax enhanced antigen presentation (PMID 28255762). If a fragment of Semax behaves that differently, an extended and capped version cannot be assumed to behave like Semax. Adamax could be more potent, longer-lasting, weaker, inactive, or active at something new; an empty record fits all of them.

Why “No Reported Side Effects” Isn’t “No Side Effects”

The commonest safety sentence about Adamax — “no side effects have been reported” — is technically true and structurally empty. Reporting requires a mechanism: adverse-event logging in trials, pharmacovigilance, case reports. Adamax has none. Absence of evidence here is absence of surveillance, not a clean result. The closest the literature gets is the 2005 Semax paper’s “minor percent of side-effects” (PMID 15792140) — a different molecule, a percent never stated.

What Users Report: Self-Reported Effects From Reddit

Because no study has ever recorded an Adamax side effect, the only descriptions of what taking it feels like come from people posting about themselves. We read the Reddit record on September 4, 2026: a site-wide search returned 55 relevant posts going back to 2018 (Adamax was a Ceretropic product before it disappeared and re-emerged in 2024–2026), and we read eight comment threads in full plus the original posts of several more, across r/Peptides, r/Biohackers, r/NooTopics, r/Nootropics, r/BodyHackGuide and r/Biohacking. The rules for what follows: every report is paraphrased and linked to its thread, no usernames are used, and every one of them is an unverified anecdote from an anonymous person about a vial whose identity and purity nobody checked. These posts can point to a pattern worth watching. They cannot establish how often anything happens, at what dose, or whether Adamax caused it.

Sleep disruption is the most consistent complaint, from at least seven different posters. One r/Biohackers user running 500 mcg intranasally every day for a week reported more frequent headaches and trouble falling asleep. A poster with ADHD who had used it for two weeks said sleep got worse and that he could not fall asleep for roughly 14 hours after a dose (r/Nootropics). Someone stacking it with P21 dosed late in the day during week one, could not sleep, and moved every dose to the morning (r/BioHackingGuide). In a 59-comment r/Biohackers thread, several first-time users reported restless sleep after a 250 mcg dose taken around 10 a.m. and either reduced the dose to 50–125 mcg or quit, one of them writing that sleep was too important to gamble with (thread). The one counter-report came from a user dosing 500 mcg subcutaneously at 6:30 a.m., who said it normalized his sleep pattern; the shared thread across all of these is timing, with evening dosing almost universally regretted (r/NooTopics).

Headache and head pressure came up from at least six posters: the more-frequent-headaches report above, a user in the 69-comment r/NooTopics thread who described the worst migraine and brain fog of his life and threw the vial away, an r/Biohacking poster who got a dull headache at three sprays per nostril, and a commenter who got a mild late-afternoon headache after an 8 a.m. dose and blamed hydration (r/BodyHackGuide). Two users in the r/Biohackers first-dose thread discussed faint head pressure that resolved after dropping to 125 mcg.

Fatigue and a post-stimulation crash is the third cluster. The clearest account is a 30-year-old on prescribed lisdexamfetamine with a prior brain injury who tried one, two and three intranasal pumps per nostril over two cycles and got fatigue at every level, falling asleep everywhere at the highest, with no cognitive benefit (r/Biohacking). In the first-dose thread, one user described intense focus at 500 mcg followed by a heavy crash from being overstimulated, the same pattern at 100 mcg, and a tolerable middle at 125 mcg; the original poster of that thread later reported a fatigue crash a couple of days after each weekly dose and fading effects that looked like tolerance. A subcutaneous user reported jitteriness if he drank coffee within two or three hours of dosing, and two r/Nootropics threads in August 2026 were devoted to the safety of combining Adamax with prescription amphetamine, a combination for which no data exists (n=1 report).

Plenty of people felt nothing. Several threads are Semax non-responders asking whether Adamax will finally work; in the NooTopics thread one user said it did nothing for him, another called it underwhelming like Semax, and the top-voted reply to a glowing report was a suggestion to have a friend blind the injections against saline. A 2021 poster took 200 and then 400 mcg and could not say he felt anything (r/Peptides), and a three-day trial in 2026 produced better mood but almost no focus benefit and a disappointed verdict (r/Biohackers). One 2025 poster mentioned dropping Semax because of hair loss and asked whether Adamax does the same; nobody reported that it did.

The identity problem runs through every thread. Users argue about whether a product is the ~1032 Da acetylated-amidated form or a ~984–986 Da base form, note that most “Adamax” sold is not the former, ask for Janoshik certificates, and question 5 mg vials. When the people reporting effects cannot agree on what molecule they took, the reports cannot be pooled.

HOW TO READ SELF-REPORTS

Insomnia, headache and a fatigue crash are exactly what a stimulant-like nootropic taken at too high a dose would be expected to produce, and exactly what expectation alone can produce in someone who paid for “Semax on steroids.” Nothing here distinguishes the two. What the record does establish is that at least a dozen people reported a problem they attributed to Adamax, which is more than the published literature has ever recorded, because the published literature has recorded nothing.

Timing: No Time Course Exists

No published data describes when Adamax effects begin, peak, or fade; any week-by-week calendar was made up. The Semax file offers fragments: the Semax fMRI change was scanned 5 and 20 min after intranasal dosing (PMID 30225715), and the EEG paroxysmal activity appeared after Semax injection, prompting advice to monitor the first injection (PMID 10199046). For Adamax, the time course of anything is a blank page.

Doses: What the Semax Studies Administered

As a description of what studies did: the 1997 Semax stroke study reported its most effective daily doses as 12 mg for moderate and 18 mg for severe strokes over 5 and 10 days (PMID 11517472); the 2018 Semax study used 2 courses of 6000 mcg/day for 10 days with a 20 day interval (PMID 29798983); the Semax fMRI study used a 1% intranasal solution (PMID 30225715). For Adamax there is no published dose, dose-response, or exposure measurement. Listings quoting Semax milligrams for Adamax transfer a dose onto a modified, heavier molecule with no data on either side. Our peptide calculator does reconstitution math and deliberately nothing else.

DID YOU KNOW

Every Semax exposure in the literature came with instruments attached — EEG mapping in the 1997 stroke study (PMID 11517472), an MRI scanner in the healthy-volunteer Semax study (PMID 30225715). Adamax has been measured by none.

Stacking Adamax: The Missing Studies

The stacks people discuss — Adamax with Adalank, with Semax, or with a stimulant — have no published studies as combinations, and Adalank has no human data of its own. The Semax literature flags one interaction: in animals, Semax augmented psychostimulant effects on central dopamine release (PMID 16996699). Its author framed that as an opportunity in ADHD; for someone pairing an untested Semax analogue with a stimulant, it is an animal interaction with no human data. Not a prediction of harm — an observation that uncertainty compounds.

The Research-Product Reality

With cagrilintide, the research-vial problem is that the vial doesn’t inherit the trials. With Adamax there are no trials to inherit. Three gaps: identity and purity (a batch-matched COA must demonstrate the published sequence and mass), concentration arithmetic (reconstitution with bacteriostatic water is on the buyer), and no reference point — no “study-grade Adamax experience” exists. Medsafe described the channel: products sold “for research purposes only” yet imported “with the intention to administer them for a therapeutic purpose” (Medsafe, June 2025). Everything here is sold strictly for non-human research use.

Sourcing and Verification

With no safety literature, product quality is the only safety variable a buyer can influence. The checklist: a batch-matched COA naming compound and quantity, with mass-spectrometry data; independent third-party testing with a verifiable report number; and skepticism toward listings citing Semax stroke trials as “clinical proof.” (Disclosure: some links on this site are affiliate links; they don’t change what we report.) Our vendor reviews show what passing documentation looks like, and our guide library covers verification in depth.

Regulatory Status and the 2025 Medsafe Flag

Adamax is not FDA-approved, has never been evaluated by the FDA, and has no development program we can find; it circulates only as a research chemical for non-human research use, as does Semax in the US. The most specific regulatory attention it has received came from New Zealand. In its June 2025 submission on unscheduled peptides, Medsafe reported 56 parcels containing peptides or SARMs intercepted at the border between 1 April 2025 and 19 May 2025, and recommended classifying ACTH analogues as prescription medicines under a group entry that “would encompass any analogues of ACTH, such as Adamax and Semax (two peptide products currently marketed as cognitive enhancers)” — to bar importation without a prescription and mitigate “both the known and unknown clinical risks” (Medsafe, June 2025). When status changes, this section changes with it.

PERSONAL OBSERVATION — PI EDITORIAL

What struck us in the Medsafe submission was its tone: a regulator obliged to write “their mechanism of action is often unknown” about compounds already arriving at its border by the parcel. Adamax is named there not because anyone studied it but because someone intercepted it. Its entire regulatory history is a seizure, not a study — and a group entry written to catch “any new/novel products with a similar chemical structure” concedes the molecules move faster than the science.

Frequently Asked Questions

What are the side effects of Adamax?

Unknown — literally. No study of Adamax in humans, animals, or cells has ever been published, so no side-effect rates exist. Lists elsewhere are borrowed from Semax, a structurally different peptide, or written from expectation.

Is Adamax safe?

No published data answers that in either direction. Nothing documents harm; nothing demonstrates safety — no study capable of measuring either has been run. Its reputation rests on inference from Semax.

Is Adamax the same as Semax?

No. Adamax is Semax’s Met-Glu-His-Phe-Pro-Gly-Pro core with an acetylated N-terminus, two extra residues, and an amidated C-terminus. Such modifications can change potency, duration, and activity, and no study has tested whether they did. Every finding attributed to Adamax was generated with Semax.

Does Semax have documented side effects?

Barely. A Semax tolerability study reported a “minor percent of side-effects” without stating the percent or naming the effects. A 73-patient Semax study in posthypoxic encephalopathy recorded EEG paroxysmal activity after injection in some cases and recommended monitoring the first injection.

Is Adamax legal?

In the US it is not an approved drug and is sold only as a research chemical for non-human research use. In New Zealand, Medsafe’s June 2025 submission recommended classifying ACTH analogues — naming Adamax and Semax — as prescription medicines, barring importation without a prescription.

Can you stack Adamax with Adalank or stimulants?

No published study has tested Adamax in any combination, and Adalank has no human data. The one relevant Semax finding is that Semax augmented psychostimulant effects on central dopamine release in animals — a different molecule, with no human data.

Glossary of Terms

  • Adamax: a designer analogue of Semax, Ac-MEHFPGPAG-NH2, with no published studies; marketed as a cognitive enhancer.
  • Semax: the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, an ACTH-fragment analogue used for stroke in Russia.
  • ACTH(4-10) / ACTH(4-7): the adrenocorticotropic hormone fragments Semax is modeled on.
  • Pro-Gly-Pro (PGP): the tripeptide at Semax’s C-terminus; alone, it behaves differently from full Semax.
  • BDNF: brain-derived neurotrophic factor; Semax raised it in stroke patients and rat brain.
  • Paroxysmal activity: abrupt abnormal EEG bursts; seen in some brain-injured patients after Semax injection.
  • Group entry: a classification covering a whole chemical class — Medsafe’s proposed tool for scheduling Adamax, Semax, and future ACTH analogues.

References